Gout: 2019 Market Spotlight – Key Pipeline & Marketed Drugs, Clinical Trials, Upcoming & Regulatory Events, Patent Information, 10-Year Disease Prevalence Forecast, Licensing & Acquisition Deals – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Gout” report has been added to ResearchAndMarkets.com’s
offering.

This report covers the Gout market, comprising key pipeline and marketed
drugs, clinical trials, upcoming and regulatory events, patent
information, a 10-year disease prevalence forecast, and licensing and
acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• The author estimates that in 2017, there were 34.5 million prevalent
  cases of gout in people aged 15 years and older worldwide, and
  forecasts that number to increase to 38.5 million prevalent cases by
  2026.
• The approved drugs in the gout space focus on a wide variety of
  targets. These are commonly administered via the oral route, with the
  remainder being available in intravenous and subcutaneous formulations.
• The majority of industry-sponsored drugs in active clinical
  development for gout are in Phase II. Early- and mid-stage drugs in
  development for gout focus on targets such as uric acid, the
  interleukin-1 receptor, URAT1, xanthine oxidase, the immune system,
  and reactive oxygen species/free radicals. The largest proportion of
  pipeline drugs are administered via the oral route, with the remainder
  being intramuscular, intravenous, or subcutaneous formulations.
• High-impact upcoming events for drugs in the gout space comprise
  topline Phase IIb trial results for REV-002 and topline Phase II trial
  results for Krystexxa.
• The overall likelihood of approval of a Phase I arthritis asset is
  10.8%, and the average probability a drug advances from Phase III is
  79.2%. Drugs, on average, take 8.2 years from Phase I to approval,
  compared to 8.7 years in the overall autoimmune/immunology space.
• There have been nine licensing and asset acquisition deals involving
  gout drugs during 2014-19. The exclusive collaboration agreement in
  2019 between Horizon Pharma and HemoShear for $500m to discover and
  develop novel therapeutics for gout was the largest deal during the
  period.
• The distribution of clinical trials across Phase I-IV indicates that
  the majority of trials for gout have been in the early and midphases
  of development, with 68% of trials in Phase I-II, and 32% in Phase
  III-IV.
• The US has a substantial lead in the number of gout clinical trials
  globally. Germany leads the major EU markets, while Japan has the top
  spot in Asia.
• Clinical trial activity in the gout space is dominated by completed
  trials. AstraZeneca has the highest number of completed clinical
  trials for gout, with 69 trials.
• AstraZeneca leads industry sponsors with the highest number of
  clinical trials for gout.

Companies Mentioned

• Ironwood
• AstraZeneca

Key Topics Covered

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

Subtypes

TREATMENT

Non-steroidal anti-inflammatory drugs (NSAIDs)

Corticosteroids

Colchicine

Combination therapy

Prevention of chronic gout

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

Uloric for Gout (January 11, 2019)

SEL-212 for Gout (April 10, 2018)

Uloric for Gout (March 12, 2018)

SEL-212 for Gout (November 7, 2017)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

Uloric U-Turn: Gout Therapy Likely To Stay On Market Despite CV Safety
Concern

Can A REMS Mitigate CV Risks? Avandia, Meridia Offer Point, Counterpoint

Is There A REMS In Uloric’s Future? US FDA Panelists Say Yes, Agency
Says Not Likely

Takeda’s Uloric: CV Mortality Signal Leads US FDA To Ponder Regulatory
Options

LIST OF FIGURES

Waiting For Next Regulatory Shoe To Drop For Takeda’s Gout Drug Uloric

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

HemoShear, Horizon Team Up To Develop Gout Therapies

Ironwood Pulls Plug On Struggling Gout Drug Zurampic

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

BIBLIOGRAPHY

Prescription information

APPENDIX

Figure 1: Trends in prevalent cases of gout, 2017-26

Figure 2: Overview of pipeline drugs for gout in the US

Figure 3: Pipeline drugs for gout, by company

Figure 4: Pipeline drugs for gout, by drug type

Figure 5: Pipeline drugs for gout, by classification

Figure 6: SEL-212 for Gout (April 10, 2018): Phase II – Chronic Gout
(Refractory)

Figure 7: Uloric for Gout (March 12, 2018): Phase IIIb – CARES (CVOT)

Figure 8: SEL-212 for Gout (November 7, 2017): Phase II – Chronic Gout
(Refractory)

Figure 9: Key upcoming events in gout

Figure 10: Probability of success in the gout pipeline

Figure 11: Licensing and asset acquisition deals in gout, 2014-19

Figure 12: Parent patents in gout

Figure 13: Clinical trials in gout

Figure 14: Top 10 drugs for clinical trials in gout

Figure 15: Top 10 companies for clinical trials in gout

Figure 16: Trial locations in gout

Figure 17: Gout trials status

Figure 18: Gout trials sponsors, by phase

LIST OF TABLES

Table 1: Prevalent cases of gout, 2017-26

Table 2: Marketed drugs for gout

Table 3: Pipeline drugs for gout in the US

Table 4: Uloric for Gout (January 11, 2019)

Table 5: SEL-212 for Gout (April 10, 2018)

Table 6: Uloric for Gout (March 12, 2018)

Table 7: SEL-212 for Gout (November 7, 2017)

Table 8: Historical global sales, by drug ($m), 2013-17

Table 9: Forecasted global sales, by drug ($m), 2019-23

For more information about this report visit https://www.researchandmarkets.com/r/qklsmi

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs, Endocrine
and Metabolic Disorders Drugs, Musculoskeletal
Disorders Drugs